Sign In
Buy ADCT
Adc Therapeutics Earnings Calls
| Release date | May 04, 2026 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.210 |
| EPS Surprise | -10.53% |
| Revenue estimate | 19.987M |
| Revenue actual | 20.851M |
| Revenue Surprise | 4.32% |
| Release date | Mar 10, 2026 |
| EPS estimate | -$0.320 |
| EPS actual | -$0.0400 |
| EPS Surprise | 87.50% |
| Revenue estimate | 22.3M |
| Revenue actual | 23.058M |
| Revenue Surprise | 3.40% |
| Release date | Nov 10, 2025 |
| EPS estimate | -$0.400 |
| EPS actual | -$0.300 |
| EPS Surprise | 25.00% |
| Revenue estimate | 21.569M |
| Revenue actual | 16.427M |
| Revenue Surprise | -23.84% |
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.360 |
| EPS actual | -$0.500 |
| EPS Surprise | -38.89% |
| Revenue estimate | 18.194M |
| Revenue actual | 18.839M |
| Revenue Surprise | 3.55% |
Last 4 Quarters for Adc Therapeutics
Below you can see how ADCT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 12, 2025 |
| Price on release | $2.94 |
| EPS estimate | -$0.360 |
| EPS actual | -$0.500 |
| EPS surprise | -38.89% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $2.64 |
| Aug 07, 2025 | $2.64 |
| Aug 08, 2025 | $2.68 |
| Aug 11, 2025 | $2.68 |
| Aug 12, 2025 | $2.94 |
| Aug 13, 2025 | $3.09 |
| Aug 14, 2025 | $3.19 |
| Aug 15, 2025 | $3.13 |
| Aug 18, 2025 | $3.24 |
| 4 days before | 11.36% |
| 4 days after | 10.20% |
| On release day | 5.10% |
| Change in period | 22.73% |
| Release date | Nov 10, 2025 |
| Price on release | $4.22 |
| EPS estimate | -$0.400 |
| EPS actual | -$0.300 |
| EPS surprise | 25.00% |
| Date | Price |
|---|---|
| Nov 04, 2025 | $4.03 |
| Nov 05, 2025 | $4.00 |
| Nov 06, 2025 | $4.16 |
| Nov 07, 2025 | $4.04 |
| Nov 10, 2025 | $4.22 |
| Nov 11, 2025 | $3.97 |
| Nov 12, 2025 | $4.05 |
| Nov 13, 2025 | $4.05 |
| Nov 14, 2025 | $3.96 |
| 4 days before | 4.71% |
| 4 days after | -6.16% |
| On release day | -5.92% |
| Change in period | -1.74% |
| Release date | Mar 10, 2026 |
| Price on release | $4.80 |
| EPS estimate | -$0.320 |
| EPS actual | -$0.0400 |
| EPS surprise | 87.50% |
| Date | Price |
|---|---|
| Mar 04, 2026 | $4.24 |
| Mar 05, 2026 | $4.19 |
| Mar 06, 2026 | $4.11 |
| Mar 09, 2026 | $4.23 |
| Mar 10, 2026 | $4.80 |
| Mar 11, 2026 | $4.88 |
| Mar 12, 2026 | $4.35 |
| Mar 13, 2026 | $4.13 |
| Mar 16, 2026 | $4.22 |
| 4 days before | 13.21% |
| 4 days after | -12.08% |
| On release day | 1.67% |
| Change in period | -0.472% |
| Release date | May 04, 2026 |
| Price on release | $3.68 |
| EPS estimate | -$0.190 |
| EPS actual | -$0.210 |
| EPS surprise | -10.53% |
| Date | Price |
|---|---|
| Apr 28, 2026 | $3.77 |
| Apr 29, 2026 | $3.78 |
| Apr 30, 2026 | $3.78 |
| May 01, 2026 | $3.83 |
| May 04, 2026 | $3.68 |
| May 05, 2026 | $3.76 |
| May 06, 2026 | $3.86 |
| May 07, 2026 | $3.76 |
| May 08, 2026 | $3.50 |
| 4 days before | -2.39% |
| 4 days after | -4.89% |
| On release day | 2.17% |
| Change in period | -7.16% |
Adc Therapeutics Earnings Call Transcript Summary of Q1 2026
ADC Therapeutics reported Q1 2026 results with net product revenues of $20.0M (versus $17.4M in Q1 2025), driven by quarter-to-quarter ordering variability and stable underlying demand for ZYNLONTA. The company highlighted several near-term clinical milestones: top-line readout for the Phase III LOTIS-5 trial (ZYNLONTA + rituximab) expected before the end of June 2026, LOTIS-7 enrollment completion in Q2 with full data by year-end, and investigator-initiated trial readouts in indolent lymphomas between late 2026 and mid-2027. Management remains blinded to LOTIS-5 data and is in a blackout/quiet period. ADC has reduced non-GAAP adjusted operating expenses by 13% year-over-year (primarily lower R&D), reported a GAAP net loss of $33M (or $0.21/share) and an adjusted net loss of $19.7M for the quarter, and ended Q1 with $231M in cash, which management expects provides runway at least into 2028. If LOTIS-5 is positive, ADC plans an sBLA submission by year-end 2026, compendia inclusion and potential commercial acceleration in 2027; management projects potential U.S. peak ZYNLONTA revenues of $600M–$1B assuming compendia listing and regulatory approvals.
